SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Merck Ends Nemtabrutinib Development After Risk-Benefit Review

Merck will discontinue Phase 3 trials BELLWAVE-011, BELLWAVE-008 and BELLWAVE-010 after reviewing the program’s data. Analyses are ongoing.

MRK

Merck is discontinuing Phase 3 BELLWAVE-011 after an external committee suggested benefits may not outweigh risks; Merck confirmed the decision after reviewing all data and will also stop the broader program, including Phase 3 BELLWAVE-008 and BELLWAVE-010. Analyses are ongoing.Material DetailsCont…

Related stories